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Serum levels of the soluble transferrin receptor (sTfR) vary depending on the
erythropoietic activity and iron status. In vitro, sTfR shed in the incubation medium corre-
lates well with cellular TfR, but this relationship has never been established in vivo. To deter-
mine the value of serum sTfR as a quantitative marker of the body mass of tissue TfR, we de-
signed experiments to examine the correlation between serum sTfR and tissue TfR in rats with




We studied changes in erythropoietic activity in normal rats as well as
in animals experiencing hemolysis, phlebotomy-induced iron deficiency, transfusion- or thia-
mphenicol-induced erythroid aplasia, or inflammation. At the end of follow-up, ferrokinetic
studies were performed and animals were sacrificed. Organs were isolated and homogenized
to determine the total mass of tissue TfR from the sum of tissue solubilized TfR in the bone
marrow, spleen, liver, and blood cells (direct method). An indirect method was developed to




As expected, serum sTfR and total mass of tissue TfR varied as a function of iron sta-
tus and erythropoiesis. Relative erythroid expansion in the spleen was greater than in the bone
marrow. With the exception of phlebotomized animals, the indirect method correlated very
















 0.0001). There was
















 0.0001). Serum sTfR represented approximately 5–6% of the total mass of tissue TfR
in most experimental situations, but this ratio was twice as high during iron-restricted eryth-
ropoiesis. In addition, the ratio could be higher or lower in nonsteady-state situations, because




Serum sTfR represents a constant proportion of the total mass of tissue TfR over
a wide range of erythropoietic activity. However, iron deficiency results in a higher proportion
of serum sTfR, and the pace of change in serum sTfR levels is slower than that of tissue TfR




Iron transport in the plasma is carried out by transferrin,
which donates iron to cells through its interaction with a
specific membrane receptor, the transferrin receptor (TfR)
[1–3]. The functional receptor is composed of two mono-
mers linked by two disulfide bridges to form a molecule of
190,000 Da. Virtually all cells, except mature red cells,
have TfR on their surface, but the largest numbers are in the
erythron, placenta, and liver. Many more TfR are seen on
colony-forming unit-erythroid than on burst-forming unit-
erythroid [4], and their numbers increase to about 300,000
on early normoblasts and up to 800,000 on intermediate
normoblasts [5], before declining to about 100,000 on retic-
ulocytes and none on mature red cells [5,6]. A soluble form
of TfR (sTfR) has been identified in animal [7] and human
serum [8]. sTfR is a truncated monomer of tissue receptor,
lacking its first 100 amino acids, which circulates in the
form of a complex of transferrin and its receptor [7–9]. The
most important determinant of serum sTfR levels appears to
be marrow erythropoietic activity, which can cause varia-








 above average normal
values [7,8]. Serum sTfR levels are decreased in situations
characterized by diminished erythropoietic activity and are
increased when erythropoiesis is stimulated. Iron status also
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influences serum sTfR levels, which are considerably ele-
vated in iron deficiency anemia and already so in functional
iron deficiency, a situation defined by tissue iron deficiency
despite adequate iron stores [10,11].
Before the discovery of serum sTfR, erythron transferrin
uptake (ETU), a refined ferrokinetic measurement of the
number of transferrin molecules taken up by erythroid TfR
per day, had been validated as the best available quantitative
measurement of total erythropoietic activity, i.e., of the total
mass of TfR-bearing erythroblasts [12,13]. We previously
showed that there was a remarkable correlation between
ETU and serum sTfR levels in rats [7] and in humans [8]
over a wide range of erythropoietic activity. However, ETU
is no longer valid when cellular TfR are not saturated by
iron-bearing transferrin, this being observed when the trans-
ferrin saturation is less than 20%. It is not known whether
serum sTfR then would remain a valid measure of the cellu-
lar TfR mass. Although experiments with leukemic cell
lines have demonstrated an excellent correlation between
cellular TfR and sTfR in the incubation medium [14,15],
this relationship has never been established in vivo for nor-
mal erythroid cells. Providing such would definitively as-
certain the value of serum sTfR as a quantitative marker of
the body mass of tissue TfR. Therefore, we designed simple
experiments to examine the correlation between serum sTfR
and the mass of tissue TfR in rats with various degrees of






Male Wistar rats were obtained from Janssen (Beerse, Belgium) and
raised at the University of Liège from the age of 3 weeks through the
end of the experiment. Animals were fed standard granular food
without iron supplements. All experiments were carried out under
ether anesthesia. Hemolytic anemia was produced by intraperitoneal
injection of 50 mg acetylphenylhydrazine per kilogram body
weight. Some animals received a single dose on day 0, and others re-
ceived three doses on days 0, 4, and 8 to obtain on-going hemolysis.
Red cell aplasia was provoked by intraperitoneal injections of thiam-
phenicol in one of three different protocols: 50 mg b.i.d. (twice
daily) for 4 consecutive days; 100 mg once daily for 10 consecutive
days; or 100 mg on days 0, 3, 6, 9 and 12. Inflammation was gener-
ated by injecting 0.25 mL of turpentine oil in each thigh. Iron-defi-
cient erythropoiesis was induced by bleeding animals 3–4 mL on 2
consecutive days and then on alternate days thereafter to maintain a
hematocrit (Hct) of about 25%–30%. To suppress erythropoiesis,
rats were transfused with 3–4 mL of washed packed red cells every
other day to maintain a hematocrit of 60–70%. Donor animals were
previously treated with thiamphenicol to induce red cell aplasia and








 per week until the
final day of the experiment, when ferrokinetic studies were per-












Fe citrate to 0.5 mL of donor plasma under continuous agitation.





into a tail vein. Blood samples were obtained from the tail vein on





) was determined by least squares regression analysis.









), plasma iron turnover (PIT, mg/dL whole blood/day) was cal-




where 0.9 is the correction for trapped plasma in the hematocrit
(0.98) and to convert venous hematocrit to whole body hematocrit
(0.92). The extravascular flux, a function of plasma iron concen-
tration [16], was subtracted to obtain tissue iron uptake (TIU), as




The effect of transferrin saturation (S) was removed by con-
verting TIU to iron-bearing transferrin uptake, and nonerythron
uptake was subtracted [12] to obtain erythron transferrin uptake




Three hours (6 hours for hypertransfused animals) after radio-
iron injection, rats were exsanguinated from the abdominal aorta
and perfused with 20–-30 mL of saline. The spleen, liver, and two
femurs were removed and weighted. Whole blood and plasma ra-
dioactivities, as well as that of liver, spleen, and femurs, were
counted. Total plasma and total red cell radioactivities were calcu-
lated from the hematocrit, assuming a blood volume of 0.07 mL/g
body weight [17]. Erythroid marrow radioactivity was estimated
by multiplying the counts of the two femurs by 6.5, because mar-
row in one femur represents 1/13 of total bone marrow in the rat
[18]. The bone marrow was extracted by 1) flushing out of the fe-
mur shafts and 2) grinding the two femur extremities and recover-
ing the supernatant after centrifugation. These two marrow compo-
nents were combined and counted. The efficiency of marrow
extraction was calculated as the ratio of radioactivity recovered to





All calculations of marrow TfR were corrected for the efficiency
of marrow extraction determined for each individual animal.
The whole spleen and extracted bone marrow, weighted ali-
quots of the liver, and washed cells from 1 mL of whole blood





Polytron PT-K homogenizer (Kinematica, Littau, Switzerland) for
1 minute at 15,000 rpm and then 0.5–2 minutes at 24,000 rpm. All
samples were homogenized in adequate amounts of 10 mM phos-
phate-buffered saline, pH 7.4, containing 1 mM iodoacetic acid,
0.5 mM PMSF, 20 U/mL aprotinin, and 2% of the nonionic deter-
gent TERIC (Sigma Chemical Corp., St. Louis, MO, USA). After









C in a Supraspeed RC28S Sorvall centrifuge (Sorvall
Instruments, Du Pont Company, Wilmington, DE, USA). The su-
pernatants were collected and counted to calculate the percentage
recovery of the original sample (ratio of radioactivity in homoge-
PIT mg/dL whole blood/day( )=
PI µg DL⁄( ) 100 Hct 0.9×–( ) 100⁄×
t1 2⁄ min( )------------------------------------------------------------------------------------------
PI 100( Hct 0.9 ) 100 0.0015×⁄×–×[ ].
TIU mg/dl whole blood/day( ) PIT=
PI 100 Hct 0.9×–( ) 100 0.0015×⁄×[ ].
ETU µM/L whole blood/day( )=
TIU 10×
56----------------------
200 2.2 S+( )
200 6.4 S+( )------------------------------- 11.–×













 6% for bone marrow. The
recovery of blood cell TfR was lower because of the radioactivity
trapped in the large volume of precipitated membrane ghosts and
hemoglobin. All calculations of solubilized tissue TfR were cor-
rected for this percentage recovery determined for each individual
sample. Solubilized tissue TfR concentration was measured on




Blood samples were drawn from a tail vein. Part of the blood was
drawn on citric acid, sodium citrate, dextrose (ACD) formula A
and part on heparin. Heparinized blood was centrifuged to obtain








C until processing. Hematocrits
were determined by the micromethod technique. Complete blood
counts were measured on a Technicon H1 automatic cell counter
(Tarrytown, NY, USA) with appropriate corrections for dilution
by ACD. The percentage of reticulocytes was determined by cytof-
luorometry on a FACSCAN cytofluorometer (Becton-Dickinson,
San Jose, CA, USA) after coloration with thiazole orange [19].
Preliminary experiments showed that this automated method gave
results similar to manual counting on blood smears colored with
brilliant cresyl blue. Serum sTfR and solubilized tissue TfR were
measured by ELISA, as previously described with minor modifica-
tions [7,20]. Serum iron (SeFe) and total iron-binding capacity
(TIBC) were measured by standard methods [21], and transferrin
saturation was derived from these figures.
 
Calculation of the mass of TfR
 
The concentration of solubilized tissue TfR measured in the super-
natant of each organ homogenate was corrected for recovery of ra-
dioactivity counted in the original sample and expressed per milli-
liter (blood cells and marrow) or gram (liver and spleen) of organ
(see earlier). The total mass of TfR in each organ was calculated
based on this concentration and the total weight (liver and spleen)
or volume (plasma, blood cells, and marrow) of the organ consid-
ered, taking into account the efficiency of organ extraction for the
bone marrow (see earlier) and multiplying the mass of the two fe-
murs by 6.5 to obtain the total TfR mass in the bone marrow. The
total body mass of tissue TfR (“total TfR mass”) was calculated as
the sum of the total masses of TfR in liver, spleen, marrow, and
blood cells.
The total mass of tissue TfR also was measured by an indirect
method in which this total mass is derived from a simple represen-
tative sample (“corporeal TfR mass”). A bone marrow sample
(i.e., femur bone marrow) is an adequate representative of all tis-
sue TfR if injected radioiron has similar access to TfR of all or-
gans. Radioactivity of such a sample truly represents radioiron up-
take by marrow TfR if there is no contamination by blood
radioactivity. To ensure this, the timing of evaluation must be such
that serum radioactivity has virtually disappeared and red cell ra-
dioactivity from newly synthesized erythroblasts has not yet left
the bone marrow. Thus, after injection of a known total amount of
radioactivity, measurements of radioactivity and solubilized TfR
in the representative sample supernatant allow calculation of the
corporeal TfR mass, based on the formula given in Equation 4:
 
(4)
Corporeal TfR mass µg( )=
Solubilized tissue TfR (ng/mL) in sample ×
Total radioactivity injected (cpm)















and expressed either in absolute values or as percentages of a base-
line value. Comparisons of baseline values with later measure-















 correlation coefficients between two variables were
computed using least squares regression equations. Most statistical
analyses were carried out using Excel 97 (Microsoft Corporation,
Redmond, WA, USA) or Prism 2.0 (GraphPad Software Inc., San




Normal animals followed-up for 16 days with blood sam-
ples drawn on alternate days showed no significant changes
in Hct, reticulocytes, or serum sTfR throughout the experi-
ment (data not shown). Compared to rats sacrificed on day
0, animals studied after a 16-day experiment had similar









and ETU, as well as total mass of tissue TfR in the various
organs and in the total body. This demonstrates that the ex-
periment by itself did not induce significant changes in
erythropoietic activity or iron metabolism.
After an acute hemolysis caused by phenylhydrazine, the
response of the erythroid compartment to the anemia be-
came rapidly apparent with peak reticulocytosis on day 5
and peak serum sTfR values on day 8 (Fig. 1A). The abso-
lute increase in the mass of tissue TfR was similar in the
spleen and bone marrow (Table 1). However, the relative
expansion of splenic TfR mass (almost 12-fold baseline)
was greater than that of the bone marrow TfR mass (2.5-
fold baseline) (Table 1). This resulted in correction of the
anemia by day 8 (Fig. 1A). As iron remained readily avail-
able, the ETU increased in proportion to the augmented TfR
mass of the erythron (Table 1). In rats receiving three injec-
tions of phenylhydrazine on days 0, 4, and 8, elevated retic-
ulocytes and serum sTfR levels were maintained through
the end of the experiment on day 14 (data not shown), re-
sulting in compensated hemolysis, i.e., correction of anemia
by day 12 despite continuing red blood cell destruction. The
expansion (19-fold) of splenic but not that of marrow TfR
mass was even more prominent than after a single injection.
The anemia maintained by repeated phlebotomies was fol-
lowed by a rapid erythroid response, as illustrated by consid-
erably elevated reticulocytes and serum sTfR (Fig. 1B). The
bone marrow could only double its TfR mass, whereas the
expansion reached 12-fold in the spleen (Table 1). However,
erythropoiesis rapidly became iron restricted, with extremely
low SeFe and transferrin saturation and increased TIBC. Ma-
jor increases in tissue TfR were observed not only in the
erythron but also in the liver, reflecting the development of
tissue iron deficiency. As a result, PIT and ETU became
gross underestimates of the mass of tissue TfR.
Hypertransfusion resulted in polycythemia-induced red
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cell aplasia (Fig. 1C). Maximal suppression of the erythroid
compartment was already achieved by day 5 (Table 2), but
serum sTfR continued to decrease slowly to stabilize only
later. ETU, but not PIT, accurately reflected the reduction in
total mass of tissue TfR. The contribution of nonerythroid
tissues, the liver, as well as other organs not analyzed here,
to the diminished total mass of tissue and thus serum sTfR
became more prominent.
Animals treated with thiamphenicol twice daily for 4
days experienced a substantial degree of erythroid suppres-
sion, then active regeneration with reticulocytes and serum
sTfR overshooting baseline levels to produce supranormal
Hct values (Fig. 2A). The mass of tissue TfR was pro-





 normal levels by day 7 and remained above normal
through day 18 (Table 2). Limited iron mobilization, illus-
trated by low Tf saturation and normal PIT and ETU despite
increased tissue TfR numbers, probably restricted the ex-
pansion of erythropoiesis. Daily injections of thiamphenicol
for 10 days (data not shown) produced a prolonged suppres-
sion of erythropoiesis (low reticulocytes, serum sTfR, tissue
TfR, and ETU) and thus a more substantial degree of ane-
mia (70% of baseline). The pattern of regeneration was sim-
ilar but amplified compared to the shorter experiment. On
the other hand, intermittent treatment on days 0, 3, 6, 9, and
12 did not bring about anemia.
Acute inflammation caused modest decrements of reticu-
locyte and serum sTfR values resulting in a moderate de-
gree of anemia after 48 hours, followed by a progressive
correction thereafter (Fig. 2B). Tf saturation and the PIT
were decreased on day 1, but no other significant change in
tissue TfR or ferrokinetic data was observed on days 1, 2, or
4 (data not shown).

































































 0.001), there was a strong
correlation between the fraction of injected radioactivity
taken up and the relative contribution of that organ to the to-
tal mass of tissue TfR. In normal animals, the fraction of in-
jected radioiron taken up in each organ was almost identical
to the proportion of body tissue TfR in that organ. However,
in situations of intense stimulation of erythropoiesis, radio-
iron uptake by blood cells became more in excess of their
relative contribution to the total tissue TfR mass. For in-
Figure 1. Evolution of hematocrit (Hct), reticulocytes, and serum sTfR levels in groups of four rats experiencing hemolysis induced by acetylphenylhydra-
zine on day 0 (A), repeatedly phlebotomized to maintain Hct around 25–30% (B), and hypertransfused with reticulocyte-poor blood to maintain Hct around
60–70% (C).
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stance, in normal rats 31%  7% of the radioactivity went
to blood cells (35%  8% of total tissue TfR mass) and
53%  3% to bone marrow (57%  8% of total tissue TfR
mass), whereas in day 9 phlebotomized animals 68%  3%
of radioactivity went to blood cells (49%  8% of total tis-
sue TfR mass) and 16%  8% to bone marrow (34%  8%
of total tissue TfR mass).
The corporeal TfR mass represents an indirect method
for estimating the total mass of tissue TfR from the total
dose of radioactivity injected and measurements of radioac-
tivity and solubilized tissue TfR in a representative marrow
sample (see Materials and methods). In phlebotomized ani-
mals, the indirect method yielded vastly exaggerated values
for total body tissue TfR, 2- to 2.5-fold higher than the
value obtained after direct measurements in the various or-
gans. In all other categories of animals, the indirect method
gave excellent results that correlated extremely well (r 
0.97, p  0001) with those of direct measurements (Fig. 3).
The total mass of serum TfR was calculated from the se-
rum sTfR concentration and plasma volume and ranged
from 8  1 g in hypertransfused animals to 199  18 g
in phlebotomized rats after 9 days (Table 3). The correlation
between ETU and the total mass of serum sTfR was excel-
lent (r  0.84, p  0.001), but only when animals with very
low (phlebotomy, recovery after thiamphenicol treatment)
or very high (hypertransfusion) SeFe levels were excluded.
The correlation between ETU and the total body mass of tis-
sue TfR was as good (r  0.90, p  0.001), provided the
same restrictions were applied (Fig. 4A). Hence, we could
establish a close relationship between the total mass of tis-
sue TfR and the total mass of serum sTfR (r  0.79, p 
0.0001) (Fig. 4B). The correlation with the total mass of tis-
sue TfR was maintained when the serum sTfR concentra-
tion was used instead of the total mass of serum sTfR (r 
0.78, p  0.0001). The total mass of serum sTfR repre-
sented approximately 5–6% of the total mass of tissue TfR
in normal animals, and this proportion was preserved in
most experimental situations (Table 3). However, this ratio
was consistently higher (around 10%) during iron-restricted
erythropoiesis induced by phlebotomies. In addition, the ra-
tio was much higher on day 4 (16%) but much lower on day
7 (2%) of thiamphenicol treatment. Finally, after hyper-
transfusion, the ratio initially increased and only progres-
sively returned to normal values because changes in tissue
TfR occurred faster than those of serum sTfR.
Discussion
In normal animals, 95% of body tissue TfR was localized in
the erythron, but this is probably an overestimate because
the modest contribution of nonerythroid organs other than
the liver was not evaluated. As mature red cells bear no TfR
and white blood cells are much less numerous and express
much fewer TfR, the blood cell TfR mass is indeed the
reticulocyte TfR mass. Tissue TfR numbers reflect cellular
iron demand and increase when either the number of TfR-
bearing cells (mostly reticulocytes and erythroblasts in
erythroid tissues) increases or the number of TfR per cell in-
creases (as in iron deficiency). Thus, in the absence of iron
deficiency, the mass of tissue TfR represents the rate of
Figure 2. Evolution of hematocrit (Hct), reticulocytes, and serum sTfR
levels in groups of four rats treated with thiamphenicol for 4 days (A) and
experiencing acute inflammation induced by turpentine oil on day 0 (B).
Figure 3. Correlation between the total mass of tissue TfR (obtained by
direct measurement in the various organs) and the corporeal mass of tissue
TfR (calculated from the analysis of a representative marrow sample after
radioiron injection). Each closed square represent a group of 3–6 animals
studied on a given day in a given condition. Open circles denote groups of
phlebotomized animals excluded from the correlation because the indirect
method was not adequate for them (see text).
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erythropoietic activity. The total mass of tissue TfR in the
erythron showed considerable plasticity, covering a 28-fold
variation from polycythemia-induced red cell aplasia to
iron-deficient anemia caused by repeated phlebotomies. The
spleen contributed considerably to the expansion of erythro-
poiesis, up to 50% of the total expansion of the tissue TfR
mass and up to 19-fold over its own baseline activity,
whereas the bone marrow attained its physiologic limit
much sooner [22,23]. This already was reported in situa-
tions of hypoxia or hemolysis- or phlebotomy-induced ane-
mia [24–26]. The mass of liver TfR remained constant in
most experimental conditions studied here, except after
phlebotomies. The latter is characterized by tissue iron defi-
ciency and thus increased expression of TfR in all cell types
[2,27]. On the other hand, iron-restricted erythropoiesis or
functional iron deficiency as produced by erythroid regener-
ation after thiamphenicol-induced red cell aplasia may
cause a more modest increase in liver TfR expression de-
spite presumably maintained iron stores. Finally, iron over-
load brought about by repeated transfusions did not trans-
late into a significant reduction in liver TfR expression. The
moderate elevation of the liver TfR mass on day 4 of thiam-
phenicol treatment remains unexplained but could be an ef-
fect of the drug itself.
The indirect method of estimating the total mass of tissue
TfR based on a representative marrow sample gave excel-
lent results that correlated extremely well with those of the
direct measurements. This implies that the contribution of
organs not examined here was minimal. This validation of
the indirect methodology makes it applicable to humans, in
whom direct measurements are impossible for obvious ethi-
cal reasons. However, the indirect method yielded vastly
exaggerated values for total body tissue TfR in phleboto-
mized animals, 2- to 2.5-fold higher than the value obtained
after direct measurements in the various organs. These rats
were characterized by massive reticulocytosis and severely
iron-restricted erythropoiesis. In addition, in situations of
intense erythropoiesis, radioiron uptake occurred preferen-
tially in the large number of reticulocytes to the disadvan-
tage of spleen or marrow erythroblasts, although they ex-
pressed comparable total numbers of TfR. Thus, it appears
that when iron is scarce relative to the demand for it, circu-
lating reticulocytes have more ready access to transferrin
iron and thus reinforce iron restriction in marrow or spleen
erythroblasts. However, this aggravation of functional iron
deficiency only occurs in the presence of massive reticulo-
cytosis, a finding rarely encountered in humans. Another
theoretical obstacle to the use of the indirect method is
when transferrin is completely saturated, allowing a signifi-
cant proportion of injected radioiron to be taken up by TfR-
independent mechanisms, particularly in hepatocytes but
also in other nonerythroid tissues. This was not encountered
in the current study. Therefore, the indirect method will re-
main valid in the vast majority of clinical situations.
We confirm here the excellent correlation between serum
TfR levels and ETU we previously reported in rats [7] and
Table 3. Relationship of the total mass of serum sTfR to the total mass of tissue TfR in rats under various conditions
N Total mass of serum sTfR (g) Total mass of tissue TfR (g) Serum sTfR/tissue TfR (%)
Normal Day 0 9 37.0  9.6 568.7  143.6 6.7  1.8
Hemolysis (PNH  1) Day 2 4 47.1  6.6 833.8  142.8* 5.7  0.8
Day 5 4 83.3  14.8*** 1816.2  144.6*** 4.6  0.9
Day 10 4 77.1  28.2* 1681.8  459.4* 4.6  0.9
Day 16 4 42.7  1.5 627.8  108.7 7.0  1.2
Hemolysis (PNH  3) Day 14 3 82.0  12.7*** 1496.9  116.8*** 5.5  0.4
Day 18 3 67.2  6.8** 957.1  46.3** 7.0  0.4
Phlebotomy Day 5 5 161.3  42.6** 1421.3  180.4*** 11.8  4.4*
Day 7 5 163.9  51.8** 1430.6  344.1** 11.3  1.1***
Day 9 4 199.1  17.5*** 1932.6  353.2** 10.6  2.0**
Day 14 8 195.1  39.7*** 2116.2  387.8*** 10.0  2.2**
Hypertransfusion Day 5 4 11.1  1.2*** 101.9  11.7*** 10.9  0.8**
Day 8 4 10.6  2.0*** 116.9  21.5*** 9.2  1.5*
Day 11 4 8.1  0.8*** 125.6  25.5*** 6.6  0.7
Day 16 4 8.3  2.2*** 102.4  21.3*** 7.9  2.5
Thiamphenicol (4 days) Day 4 4 28.7  4.2 160.2  63.1*** 15.5  3.1***
Day 7 3 47.0  9.0 2030.5  128.7*** 2.3  0.6**
Day 11 3 48.1  1.6* 974.8  287.5** 5.2  1.5
Day 18 4 53.1  10.3* 984.3  140.7*** 5.4  0.9
Thiamphenicol (9 days) Day 10 3 12.6  3.8* 152.5  39.6** 8.2  0.5
Inflammation Day 1 4 29.7  2.3 545.3  86.7 5.5  0.8
Day 2 4 45.4  6.8 543.4  216.5 9.0  2.0
Day 4 4 42.2  7.3 576.3  191.8 8.3  3.9
PNH  phenylhydrazine.
*P  0.05; **P  0.01; ***P  0.001.
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in humans [8,20,28]. This relationship allowed development
of the serum sTfR assay as a quantitative measurement of
total erythropoietic activity. However, ETU will be overes-
timated when SeFe is very high because an unknown pro-
portion of radioiron will go to nonerythroid tissues through
TfR-independent mechanisms [29]. More frequently, when
there are not enough transferrin-bearing molecules to satu-
rate tissue TfR, iron uptake will be reduced and ETU will be
largely underestimated. The iron supply will become inade-
quate when transferrin saturation is less than 20% or the rate
of radioiron disappearance from the plasma is less than 25
minutes [29]. This functional iron deficiency was encoun-
tered in experiments of phlebotomy or regeneration after
thiamphenicol-induced red cell aplasia.
Serum sTfR correlated very well with tissue TfR, repre-
senting 5–8% of the total mass of tissue TfR in normal ani-
mals as well as in situations of expanded or suppressed
erythropoietic activity (Table 3). In vitro experiments with
K562 or HL-60 cells evidenced parallel changes between
cellular TfR and sTfR in the supernatant [14,15]. Soluble
TfR in the supernatant was approximately 5% of the cellular
TfR over a wide range of cellular iron [14]. This is remark-
ably similar to our results obtained in vivo. However, there
were two exceptions. First, iron-restricted erythropoiesis
was associated with serum sTfR/tissue TfR ratios signifi-
cantly higher than in iron-replete animals. This has not been
directly demonstrated during 24-hour incubation experi-
ments in transferrin-containing medium [14]. However, the
kinetics of sTfR release in vivo could be different; for in-
stance, sTfR release could go on well beyond 24 hours in
vivo if iron availability is restricted. Such a hypothesis is
supported by the demonstration of a protective effect of
TfR-free diferric transferrin against sTfR shedding in vitro
[30]. The insufficient presence of iron-bearing transferrin
relative to the number of tissue TfR could promote sTfR re-
lease in iron deficiency. The second exception is encoun-
tered in situations characterized by rapidly changing eryth-
ropoiesis. The evolution of rats treated with thiamphenicol
for 4 days illustrates best the discrepancies between tissue
TfR and serum sTfR in situations characterized by fast, pro-
found changes in erythropoietic activity. Whereas the tissue
TfR mass was only 20% of normal on day 4 and increased
up to 3.5 normal on day 7 (Table 2), changes in serum
sTfR levels could not keep up with these rapid modifica-
tions of erythropoietic activity and remained within 40% of
baseline values (Fig. 2A). Ratios of serum sTfR/tissue TfR
lost their meaning until the situation later stabilized (Table
3). Fortunately, such wild variations of erythropoiesis are
seldom seen in patients, even after stem cell transplantation
[31,32], and the delay between modifications in erythroblast
number and serum sTfR changes is only a few days. After
hypertransfusion, changes in tissue TfR occur faster than
changes in serum sTfR, such that the ratio initially increases
before progressively returning to baseline values.
Little is known about the rate of production and the
clearance of sTfR in vivo, but the current study may provide
some indirect clues. The small decrease of serum sTfR lev-
els despite early major reductions in the number of tissue
TfR in rats treated with thiamphenicol (Fig. 2A, and Tables
2 and 3), the persistence of elevated serum sTfR levels in
the face of complete normalization of tissue TfR 16 days af-
ter an acute hemolytic episode (Fig. 1A, and Tables 1 and
3), and the continuing decrease of serum sTfR values de-
spite stable suppression of erythropoiesis induced by poly-
cythemia (Fig. 1C, and Tables 2 and 3) all suggest that the
clearance of serum sTfR is quite slow. On the other hand,
the consistent early decrease of serum sTfR values without
significant change in the mass of tissue TfR in any organ
suggests that an acute inflammation could accelerate the
clearance of sTfR from the serum. However, it is possible
that lower serum sTfR values were only the result of an ex-
pansion of plasma volume mediated by cytokines such as
interleukin-6 [33,34].
In conclusion, serum sTfR accurately represents a con-
stant proportion (around 6%) of the total mass of tissue TfR
over a wide range of different rates of erythropoietic activ-
ity. However, iron-deficient erythropoiesis is associated
with higher levels of serum sTfR relative to tissue TfR, and
Figure 4. Correlation between the total mass of tissue TfR and the ETU
(A) or the total mass of serum sTfR (B). Open circles denote the groups of
animals with very low or very high serum iron that are excluded from the
correlation with the ETU because the ETU was not correctly evaluated for
them (see text).
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the pace of change in serum sTfR levels is slower than that
of the tissue TfR mass.
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